Mesoblast Limited

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the required period for any antitrust objection under the United States Hart-Scott-Rodino(HSR) anti-trust improvement Act 1976 in respect of its acquisition of Angioblast Systems Inc. has expired.

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) announced that positive preclinical trial results were today presented at the American Heart Association's annual conference in Chicago showing that the company's proprietary allogeneic stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

Regenerative medicine company, Mesoblast Limited (ASX:MSB) (USOTC:MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded $1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that interim results from its Phase 2 clinical trial for minimally invasive posterior lumbar spinal fusion showed that its proprietary "off-the-shelf" product NeoFuse (TM) was both safe and effective.

Stockholders of United States adult stem cell company Angioblast Systems Inc. voted unanimously at a special stockholders' meeting held 19 October in favour of becoming a wholly-owned subsidiary of publicly listed global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY).

Australian regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it is broadening the oncology applications of its "off-the-shelf" cell product for expansion of haematopoietic stem cells in patients with blood cancers.

Shareholders of Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today overwhelmingly approved the acquisition of its United States associate company, Angioblast Systems Inc.

Mesoblast Limited (ASX:MSB) (PINK:MBLTY) is pleased to release its Chairman Brian Jamieson's speech at the Extraordinary General Meeting.

Clinical advances by regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) were featured prominently at the 39th annual meeting of the International Society for Experimental Hematology (ISEH) and the Tissue Engineering and Regenerative Medicine International Society (TERMIS) Asia Pacific meeting, both held over the past several days.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today reported its results for the year ended 30 June 2010.